Serum Calretinin as a Biomarker in Malignant Mesothelioma

The early diagnosis of malignant mesothelioma (MM) could improve the prognosis of MM patients. To confirm an MM diagnosis, an immunohistochemical analysis of several tumor tissue markers, including calretinin, is currently required. Our aim is to evaluate serum calretinin as a potential biomarker in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cita Zupanc, Alenka Franko, Danijela Štrbac, Metoda Dodič Fikfak, Viljem Kovač, Vita Dolžan, Katja Goričar
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	malignant mesothelioma calretinin asbestos-related disease biomarker Medicine R
Acceso en línea:	https://doaj.org/article/edcf4814866c47509e6a48e4eb336d3d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:edcf4814866c47509e6a48e4eb336d3d
record_format	dspace
spelling	oai:doaj.org-article:edcf4814866c47509e6a48e4eb336d3d2021-11-11T17:32:03ZSerum Calretinin as a Biomarker in Malignant Mesothelioma10.3390/jcm102148752077-0383https://doaj.org/article/edcf4814866c47509e6a48e4eb336d3d2021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/4875https://doaj.org/toc/2077-0383The early diagnosis of malignant mesothelioma (MM) could improve the prognosis of MM patients. To confirm an MM diagnosis, an immunohistochemical analysis of several tumor tissue markers, including calretinin, is currently required. Our aim is to evaluate serum calretinin as a potential biomarker in asbestos-related diseases, especially in MM. Our study includes 549 subjects: 164 MM patients, 117 subjects with asbestosis, 195 subjects with pleural plaques and 73 occupationally asbestos-exposed subjects without asbestos-related diseases. The serum calretinin concentration was determined with a commercially available enzyme immunoassay. Data on the soluble mesothelin-related peptides (SMRP) concentration are available from previous studies. MM patients had a significantly higher calretinin concentration than subjects without disease, subjects with pleural plaques or subjects with asbestosis (all <i>p</i> < 0.001). The histological type was significantly associated with serum calretinin: patients with sarcomatoid MM had lower calretinin than patients with the epithelioid type (<i>p</i> = 0.001). In a ROC curve analysis, the area under the curve for calretinin concentration predicting MM was 0.826 (95% CI = 0.782–0.869; <i>p</i> < 0.001). At the cutoff value of 0.32 ng/mL, sensitivity was 0.683, while specificity was 0.886. The combination of calretinin and SMRP had the highest predictive value. Calretinin is a useful biomarker that can distinguish MM from other asbestos-related diseases and could, therefore, contribute to an earlier non-invasive diagnosis of MM.Cita ZupancAlenka FrankoDanijela ŠtrbacMetoda Dodič FikfakViljem KovačVita DolžanKatja GoričarMDPI AGarticlemalignant mesotheliomacalretininasbestos-related diseasebiomarkerMedicineRENJournal of Clinical Medicine, Vol 10, Iss 4875, p 4875 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	malignant mesothelioma calretinin asbestos-related disease biomarker Medicine R
spellingShingle	malignant mesothelioma calretinin asbestos-related disease biomarker Medicine R Cita Zupanc Alenka Franko Danijela Štrbac Metoda Dodič Fikfak Viljem Kovač Vita Dolžan Katja Goričar Serum Calretinin as a Biomarker in Malignant Mesothelioma
description	The early diagnosis of malignant mesothelioma (MM) could improve the prognosis of MM patients. To confirm an MM diagnosis, an immunohistochemical analysis of several tumor tissue markers, including calretinin, is currently required. Our aim is to evaluate serum calretinin as a potential biomarker in asbestos-related diseases, especially in MM. Our study includes 549 subjects: 164 MM patients, 117 subjects with asbestosis, 195 subjects with pleural plaques and 73 occupationally asbestos-exposed subjects without asbestos-related diseases. The serum calretinin concentration was determined with a commercially available enzyme immunoassay. Data on the soluble mesothelin-related peptides (SMRP) concentration are available from previous studies. MM patients had a significantly higher calretinin concentration than subjects without disease, subjects with pleural plaques or subjects with asbestosis (all <i>p</i> < 0.001). The histological type was significantly associated with serum calretinin: patients with sarcomatoid MM had lower calretinin than patients with the epithelioid type (<i>p</i> = 0.001). In a ROC curve analysis, the area under the curve for calretinin concentration predicting MM was 0.826 (95% CI = 0.782–0.869; <i>p</i> < 0.001). At the cutoff value of 0.32 ng/mL, sensitivity was 0.683, while specificity was 0.886. The combination of calretinin and SMRP had the highest predictive value. Calretinin is a useful biomarker that can distinguish MM from other asbestos-related diseases and could, therefore, contribute to an earlier non-invasive diagnosis of MM.
format	article
author	Cita Zupanc Alenka Franko Danijela Štrbac Metoda Dodič Fikfak Viljem Kovač Vita Dolžan Katja Goričar
author_facet	Cita Zupanc Alenka Franko Danijela Štrbac Metoda Dodič Fikfak Viljem Kovač Vita Dolžan Katja Goričar
author_sort	Cita Zupanc
title	Serum Calretinin as a Biomarker in Malignant Mesothelioma
title_short	Serum Calretinin as a Biomarker in Malignant Mesothelioma
title_full	Serum Calretinin as a Biomarker in Malignant Mesothelioma
title_fullStr	Serum Calretinin as a Biomarker in Malignant Mesothelioma
title_full_unstemmed	Serum Calretinin as a Biomarker in Malignant Mesothelioma
title_sort	serum calretinin as a biomarker in malignant mesothelioma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/edcf4814866c47509e6a48e4eb336d3d
work_keys_str_mv	AT citazupanc serumcalretininasabiomarkerinmalignantmesothelioma AT alenkafranko serumcalretininasabiomarkerinmalignantmesothelioma AT danijelastrbac serumcalretininasabiomarkerinmalignantmesothelioma AT metodadodicfikfak serumcalretininasabiomarkerinmalignantmesothelioma AT viljemkovac serumcalretininasabiomarkerinmalignantmesothelioma AT vitadolzan serumcalretininasabiomarkerinmalignantmesothelioma AT katjagoricar serumcalretininasabiomarkerinmalignantmesothelioma
_version_	1718432094155177984

Serum Calretinin as a Biomarker in Malignant Mesothelioma

Ejemplares similares